![]() ![]() In the new study, first author Alvaro Cobo-Calvo, MD, PhD, project leader Romain Marignier, MD, PhD, a professor in the neuroinflammation service at the Hôpital Neurologique Pierre Wertheimer in Lyon, France, and colleagues from across France compared clinical features, disease course, and antibody dynamics among 98 children (age<18 years) and 268 adults with MOGAD. Other researchers have noted differences in the disease between children and adults, but few studies have comprehensively compared them in a large cohort. While antibodies to MOG have been detected for many years, MOGAD itself has been recognized as a distinct disease only since 2013. MOG antibody disease (or MOG antibody-associated disease, MOGAD) is caused by the autoimmune production of antibodies against MOG, located on the surface of the myelin sheath, and thought to be responsible for cell adhesion as well as other functions. “But as we have been able to do antibody tests on more and more patients, we have come to recognize that it actually has a broader spectrum of features, and one of the biggest points of stratification is age.”Ĭhildren and adults “really do have different disease courses and different manifestations,” he said. “We used to think of this disease as having a single phenotype,” commented Michael Levy, MD, PhD, FAAN, director of the Neuromyelitis Optica Clinic and Research Laboratory and research director of the division of neuroimmunology and neuroinfectious disease at Massachusetts General Hospital, who was not involved in the study. That was among the findings of a five-year, nationwide analysis of more than 350 patients with the disease in France, one of the first to delineate the differences in clinical features and prognosis of children and adults. Young children with an initial episode of myelin oligodendrocyte glycoprotein (MOG) antibody disease have a better outcome and lower risk for relapse than adults, according to a study published on September 21 in Annals of Neurology. New research suggests young children with an initial episode of myelin oligodendrocyte glycoprotein antibody disease have better outcomes and a lower risk for relapse than adults. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |